Multiple Catalysts Prompted The London Company Small-Mid Cap Strategy’s Cooper Companies (COO) Addition

Cooper Companies (COO) has been added to The London Company's Small-Mid Cap Strategy portfolio, representing a tactical positioning decision within an active small-to-mid cap equity framework. The addition occurred during a period of notable market volatility in early 2026, following a challenging March downturn that pressured both the Russell 3000 and broader equity indices.

The addition reflects multiple catalyst-driven reasons, though the investor letter summary does not fully enumerate them. This suggests the fund manager identified fundamental inflection points or valuation opportunities in COO's business that justified portfolio allocation despite near-term market headwinds. Small-cap allocations typically respond to differentiated company-level narratives rather than macro correlations.

COO operates at the intersection of ophthalmology and vision care markets, exposing the portfolio to healthcare demand dynamics and aging demographics. The timing of this addition—amid broader equity selloff—may indicate conviction on company-specific recovery or operational execution rather than sector tailwinds, given Health Care's mixed performance in early 2026.

Sector implication: This move signals selective confidence in Health Care equities at smaller market caps, where valuation compression created opportunity. Portfolio flows into individual positions during downturns typically precede accumulation phases when sentiment reverses.